EUVIMEDUpptäck EUVIMED
CrossrefInfokort

Protective effects of ivermectin against ischemia-reperfusion-induced ovarian injury in rats

Nesrin Yilmaz, Seval Bulut, Seyma Ilayda Paltaci, Renad Mammadov, Cengiz Sarigul, Mustafa Ozkaraca, Behzat Tebrizi, Halis Suleyman

Frontiers in Pharmacology · 2026-11-04 · 17

DOI: 10.3389/fphar.2026.2003125 ↗
AbstractBibliografiska uppgifter

Abstract

Background Ovarian ischemia-reperfusion (I/R) injury induces severe tissue damage through oxidative stress and inflammation, and DNA damage. This study investigated the protective effects of short- and long-term ivermectin application against ovarian I/R injury in rats. Methods Twenty-four female Wistar albino rats were divided into four groups: sham operation (SOG), ovarian I/R (OIR), long-term ivermectin-applied I/R (LIOIR), and short-term ivermectin-applied I/R (SIOIR). Ovarian torsion was maintained for 3 h before detorsion. Ivermectin (2 mg/kg, orally) was administered for 3 or 6 days. Ovarian malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) were measured. Histopathological and immunohistochemical analyses of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were also performed. Results OIR increased MDA and reduced tGSH, SOD, and CAT. Three-day ivermectin pretreatment normalized oxidative stress marker levels to values comparable to those in the sham group, whereas six-day pretreatment provided no significant protection. Follicular degeneration was pronounced in OIR and LIOIR but markedly attenuated in SIOIR. Immunohistochemistry demonstrated preserved COX-1 expression and reduced COX-2 and 8-OHdG immunoreactivity following short-term ivermectin pretreatment. Conclusion Short-term ivermectin effectively protected ovarian tissue against experimental I/R injury by reducing oxidative stress, inflammation, and DNA damage, whereas prolonged pretreatment failed to provide comparable protection, supporting its therapeutic potential.

Kunskap som passar ditt arbete.

Från en kostnadsfri start via personlig litteratursökning till hela Research Suite.

Visa priser →

Ingår alla förlagsfulltexter?

Nej. Bibliografiska poster, abstrakt och fulltexter är olika typer av innehåll. Om en fulltext är tillgänglig beror på källan, Open Access och dina befintliga licenser. En EUVIMED-plan ersätter inga ytterligare förlagsrättigheter.

Visa priser →